Stablecoin Development Corporation · AMEX:SDEV
Stablecoin Development — NovaBay Pharmaceuticals — Investor Presentation (January 2020)
13 slides from Stablecoin Development's investor presentation, January 2020
Slide 1: Investor Presentation
Investor Presentation January 2020 Justin M. Hall CEO and General Counsel NYSE America: NBY www.NovaBay.com www.Avenova.com www.CelleRx.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of applicable U.S. securities laws, which statements can, in some cases, be identified with terms such as “project,” “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,”
Slide 3: Investment Highlights
Investment Highlights • New direct-to-consumer channel for prescription-strength Avenova on Amazon.com improves product accessibility • Aligns with strategy for cost-efficient growth and builds on Avenova‘s postion as #1 prescribed lid and lash spray • Accounts for 36% of unit sales in Q3, first ful
Slide 4: Neutrox is Pure Hypochlorous Acid
Neutrox is Pure Hypochlorous Acid Neutrox is the active ingredient in Avenova, CellerRx and NeutroPhase I FDA-cleared as 510(k) medical device Natural Molecule Hypochlorous Acid (HOCl) Advantages • Kills bacteria but is non-resistant unlike antibiotics • Highly effective against microbial invaders C
Slide 5: Avenova Advantages
Avenova Advantages Effectively treats MGD and blepharitis, representing 86% of all chronic dry eye disease Overcomes limitations of competing therapies Addresses the underlying cause, not merely the symptoms Safe for continuous daily use 5
Slide 6: Defined Strategy Across 3 Distribution Channels
Defined Strategy Across 3 Distribution Channels Rx Sales Prescription Ophthalmologists (40 mL) Buy-and-Sell Optometrists (20 mL) Direct- to-Consumer Patients (20 mL) 6
Slide 7: Journey of Avenova
Journey of Avenova The Growth of a Product, along with the Rise and Fall of Insurance Reimbursement 1 pioneering 645 prescribers 7,425 prescribers 8,297 prescribers 12,000 prescribers 15,000 nationwide ophthalmologist prescribers prescribing Avenova Converted contract sales force into regular, Align
Slide 8: 2019 Shift in U.S. Avenova Commercialization Strategy
2019 Shift in U.S. Avenova Commercialization Strategy Proactive response to evolving reimbursement environment to support sales growth and maintain cost effectiveness • Launched NovaSight and NovaWipes on Amazon.com; Avenova companion products to drive cost-effective growth and leverage • Introduced
Slide 9: Avenova Direct on Amazon.com
Avenova Direct on Amazon.com Prescription-strength Avenova available for the first time without a prescription • Improves patient access through Amazon.com’s rapid and efficient product distribution launched on June 1, 2019 • Capitalizes on trend of marketing pharmaceuticals directly to consumers, a
Slide 10: Avenova Companion Products
Avenova Companion Products NovaSight NovaWipes Proprietary daily vitamin and mineral supplement Dry, soft, hypoallergenic and absorbable wipe for launched on Amazon.com use in applying Avenova • Formulated by well-known, board-certified • Specially designed for use when applying ophthalmologist Aven
Slide 11: CelleRx Direct-to-Consumer Launch
CelleRx Direct-to-Consumer Launch CelleRx is a topical solution specially designed for post-procedure use to gently cleanse skin • Non-antibiotic, non-alcohol formulation • Topical anti-inflammatory properties • Soothing to the skin • Ready to use, non-drying and doesn’t stain • Post-procedure appli
Slide 12: Q3 Financial Highlights
Q3 Financial Highlights Early success of shift in U.S. commercialization strategy to support Avenova sales growth while maintaining cost effectiveness • Avenova sales of $1.6 million, units sales up 16% from Q2 despite significant reduction in field sales force • Avenova Direct contributes 36% of un
Slide 13: Summary
Summary • New direct-to-consumer channel for Avenova on Amazon.com improves product accessibility • Launches of NovaSight and NovaWipes on Amazon.com capitalize on Avenova companion product sales • Introduction of direct-to-consumer, prescription-strength CelleRx for acute skin care supports additio
NovaBay Pharmaceuticals — Investor Presentation (January 2020) on 6ix